A trial of KTE-C19 for the treatment of chronic lymphocytic leukaemia

Trial Profile

A trial of KTE-C19 for the treatment of chronic lymphocytic leukaemia

Planning
Phase of Trial: Phase I/II

Latest Information Update: 19 Oct 2016

At a glance

  • Drugs Axicabtagene ciloleucel (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Acronyms ZUMA-8
  • Most Recent Events

    • 19 Oct 2016 According to a Kite Pharma media release, this trial is expected to enroll the first patient in 2017.
    • 19 Oct 2016 Planned initiation date changed from 1 May 2015 to 1 Jan 2017, as reported by a Kite Pharma media release.
    • 02 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top